Skip to content

Trial Summary

ICON 9 will assess the efficacy, safety and tolerability of maintenance olaparib in combination with cediranib compared to maintenance olaparib alone following a response to platinum-based chemotherapy in women with relapsed platinum-sensitive ovarian cancer following a response to platinum-based chemotherapy.

Acronym:

ICON9

ACTRN/NCT /ethics:

NCT03278717

Scientific title:

Study Evaluating the Efficacy of Maintenance Olaparib and Cediranib or Olaparib Alone in Ovarian Cancer Patients

Sponsor / Cooperative group:

University College, London

Trial & Patient Characteristics

Cancer TypeGynaecological
Trial TypeTreatment
PhasePhase III
Age Range18 years and older
SexFemale
Tumour Stream -
Cancer StageLocally Recurrent or Locally Advanced
Anticipated Start Date2018-06-15
Anticipated End Date2023-12-01

Participating Hospitals

HospitalFlinders Medical Centre
Clinical Trial CoordinatorAlex Scott-Hoy
Emailalex.scott-hoy@sa.gov.au
Phone08 8204 4830
Principal InvestigatorDr Ganessan Kichenadasse
Recruitment StatusRecruiting